(Q68155568)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

author name string

E. M. Massarotti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605152

14 October 2022

N. Y. Liu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605152

14 October 2022

J. Mier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605152

14 October 2022

M. B. Atkins

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605152

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1605152

14 October 2022

publication date

1 June 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

22 September 2019

https://api.elsevier.com/content/article/PII:000293439290789E?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

https://api.elsevier.com/content/article/PII:000293439290789E?httpAccept=text/plain

14 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

American Journal of Medicine

14 October 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

693-697

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

22 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

14 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

14 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Interleukin-2 augments natural killer cell activity

14 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Fibromyalgia and interleukin-2 therapy for malignancy

14 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

14 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

14 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Nosocomial sepsis associated with interleukin-2.

14 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

Palmar fasciitis and polyarthritis associated with ovarian carcinoma

14 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90789-E

14 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1605152%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference